ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore mechanism of
methodsSixty male C57BL/6 mice were randomized equally into control group, MPTP group, low-, medium-, and high-dose WSYG groups (daily dose 10, 20 and 40 g/kg by gavage, respectively), and selegiline group. In all but the control group, the mice received intraperitoneal injections of MPTP (30 mg/kg) for 6 consecutive days to induce subacute PD. Motor function of the mice was assessed by the pole and open field tests, and striatal tyrosine hydroxylase (TH) expression, neuronal damage and intestinal histopathology were evaluated using immunohistochemistry, Nissl staining, and HE staining. Serum levels of diamine oxidase(DAO), D-lactic acid (D-LA), lipopolysaccharide (LPS), vasoactive intestinal peptide (VIP), and cholecystokinin (CCK) were measured by ELISA, intestinal expressions of tight junction proteins zonula occludens-1 (ZO-1) and occludin were an alyzed by immuno fluorescence staining, and intestinal barrier permeability was assessed using FITC-dextran.
resultsWSYG, especially at the medium and high doses, significantly improved the performance of the mice in the behavioral tests. WSYG at all the 3 doses reduced neuronal damage and Nissl body loss in the striatum and substantia nigra, its medium and high doses significantly increased TH-positive neurons in the striatum. WSYG at the 3 doses significantly decreased serum FITC-Dextran (MW 4000) level, and medium- and high-dose WSYG markedly alleviated colonic inflammatory infiltration and edema, increased the chorionic crypt ratio, and reduced loss of ZO-1 and occludin. WSYG at all the 3 doses significantly increased serum VIP and CCK levels and decreased DAO, D-LA and LPS levels in the mice.
conclusionsWSYG effectively improve motor deficits and intestinal dysfunction in PD mice possibly by up-regulating intestinal VIP/CCK and down-regulating DAO/D-LA/LPS expressions to reduce intestinal barrier permeability, thereby alleviating dopaminergic neuronal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.